|
1. Biologie
|
|
|
Gene Sequencing Study Reveals Unusual Mutations in Endometriosis [Johns Hopkins]
|
|
|
|
|
|
For
reasons the researchers say are not yet clear, the mutations they
identified have some links to genetic mutations found in some forms of
cancer. They emphasize that although abnormal tissue growth in
endometriosis often spreads throughout the abdominal cavity, the tissue
rarely becomes cancerous except in a few cases when ovaries are
involved.
|
|
|
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.14 Dép., diag. & prono. - Thyroïde
|
|
|
|
4.5 Dép., diag. & prono. - Colorectal
|
|
|
Gut Check: This Smart Capsule Is Making Colon-Cancer Screening Easier To Swallow [GE]
|
|
|
|
|
|
Users
simply swallow the device, which is roughly the size of a large
vitamin, and then the device spends the next two to three days traveling
through the digestive tract, scanning the inside of the colon with
precisely timed X-rays. It wirelessly transmits information to a data
recorder that users attach to their backs. Doctors then collect the data
recorder and analyze the data.
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
Collection of Patient-Reported Outcomes Feasible in Cancer Clinical Trials [NCI]
|
|
|
|
|
|
Overall,
patient-reported outcomes were successfully collected at 86% of
scheduled visits. The most common reasons that the data could not be
collected were missed clinic appointments, simple oversights (such as
forgetting to provide tablet computers to participants), and technical
problems (such as computer malfunctions or Internet connectivity
issues).
|
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
Progress on science, medicines and health [EMA]
|
|
|
|
|
|
In
2016, the Agency recommended a marketing authorisation for 81 medicines
for human use, including 27 new active substances. Many of these
innovative substances build on the advances made in biomedical science
and have the potential to make a difference for patients.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Drug Money [National Post]
|
|
|
|
|
|
“It
is becoming increasingly difficult to disregard the costs of these new
therapies — side-effect costs, costs to quality of life and financial
costs … especially when the benefits are very, very small,” said Dr.
Chris Booth, an oncology professor and researcher at Queen’s University
in Kingston, Ontario. “The vast majority … are associated with extremely
modest advances.”
|
|
|
|
|
|
|
5.5.1.1 ASCO (général) - Industriels
|
|
|
|
6. Lutte contre les cancers
|
|
|
Seeking a Second Opinion [Cancer Research Catalyst]
|
|
|
|
|
|
There
is relatively little research on the impact of seeking input from a
second doctor, but those studies that exist suggest that second opinions
can result in significant changes in treatment, writes contributor
Stephen Ornes in an article published in the spring 2017 issue of Cancer
Today.
|
|
|
|
|
|
|
Opioids in Oncology Care [Oncology Times]
|
|
|
|
|
|
When
using opioids, the provider should assess risk for addiction and
provide education to the patient of potential adverse effects. Ongoing
monitoring and assessment of the four A’s are important and
documentation of improvement in function and quality of life is always
the goal.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
6.11 Patients
|
|
|
|
6.6 Publications
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|